Risk Assessment and Risk Minimization in Nanomedicine: A Need for Predictive, Alternative, and 3Rs Strategies
暂无分享,去创建一个
Claudia Giachino | Caterina Cristallini | Lisa Accomasso | C. Cristallini | C. Giachino | L. Accomasso | Lisa Accomasso
[1] Igor Linkov,et al. A weight of evidence approach for hazard screening of engineered nanomaterials , 2014, Nanotoxicology.
[2] C. Grady,et al. What makes clinical research ethical? , 2000, JAMA.
[3] K. Stockdale,et al. Ethics in the OR , 1993 .
[4] Peter Kearns,et al. Physico-chemical properties of manufactured nanomaterials - Characterisation and relevant methods. An outlook based on the OECD Testing Programme , 2018, Regulatory toxicology and pharmacology : RTP.
[5] A Worth,et al. Towards an alternative testing strategy for nanomaterials used in nanomedicine: Lessons from NanoTEST , 2015, Nanotoxicology.
[6] Jeremy C Simpson,et al. High-content analysis for drug delivery and nanoparticle applications. , 2015, Drug discovery today.
[7] Daniel L Villeneuve,et al. Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment , 2010, Environmental toxicology and chemistry.
[8] Claudia Giachino,et al. Stem Cell Tracking with Nanoparticles for Regenerative Medicine Purposes: An Overview , 2015, Stem cells international.
[9] Sonja Boland,et al. Toxicity evaluation of engineered nanoparticles for medical applications using pulmonary epithelial cells , 2015, Nanotoxicology.
[10] Susan Wijnhoven,et al. Risk assessment frameworks for nanomaterials: Scope, link to regulations, applicability, and outline for future directions in view of needed increase in efficiency , 2018 .
[11] Nancy M. P. King,et al. Nanomedicine First-in-Human Research: Challenges for Informed Consent , 2012, Journal of Law, Medicine & Ethics.
[12] Lang Tran,et al. ITS-NANO - Prioritising nanosafety research to develop a stakeholder driven intelligent testing strategy , 2014, Particle and Fibre Toxicology.
[13] Fritz Allhoff,et al. The Coming Era of Nanomedicine , 2009, The American journal of bioethics : AJOB.
[14] Xiang Wang,et al. Nanomaterial toxicity testing in the 21st century: use of a predictive toxicological approach and high-throughput screening. , 2013, Accounts of chemical research.
[15] J A Shatkin,et al. Alternative Testing Strategies for Nanomaterials: State of the Science and Considerations for Risk Analysis , 2016, Risk analysis : an official publication of the Society for Risk Analysis.
[16] Guangchao Chen,et al. Current Knowledge on the Use of Computational Toxicology in Hazard Assessment of Metallic Engineered Nanomaterials , 2017, International journal of molecular sciences.
[17] Michael Riediker,et al. Therapeutic nanoparticles in clinics and under clinical evaluation. , 2013, Nanomedicine.
[18] Lutz Mädler,et al. Use of metal oxide nanoparticle band gap to develop a predictive paradigm for oxidative stress and acute pulmonary inflammation. , 2012, ACS nano.
[19] D. Golde. The stem cell. , 1991, Scientific American.
[20] David A Winkler,et al. Recent advances, and unresolved issues, in the application of computational modelling to the prediction of the biological effects of nanomaterials. , 2016, Toxicology and applied pharmacology.
[21] Maria Dusinska,et al. Biological impact assessment of nanomaterial used in nanomedicine. Introduction to the NanoTEST project , 2015, Nanotoxicology.
[22] Thomas Hartung,et al. Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice , 2013, Archives of Toxicology.
[23] T. Hartung. Toxicology for the twenty-first century , 2009, Nature.
[24] J. Lovrić,et al. Nanotherapeutics in the EU: an overview on current state and future directions , 2014, International journal of nanomedicine.
[25] Eleonore Fröhlich,et al. Role of omics techniques in the toxicity testing of nanoparticles , 2017, Journal of Nanobiotechnology.
[26] Bryant C Nelson,et al. Emerging metrology for high-throughput nanomaterial genotoxicology. , 2017, Mutagenesis.
[27] Linda F. Hogle,et al. Concepts of Risk in Nanomedicine Research , 2012, Journal of Law, Medicine & Ethics.
[28] Emil Cimpan,et al. An impedance-based high-throughput method for evaluating the cytotoxicity of nanoparticles , 2013 .
[29] David B Resnik,et al. Ethics in nanomedicine. , 2007, Nanomedicine.
[30] A E Nel,et al. Implementation of alternative test strategies for the safety assessment of engineered nanomaterials , 2013, Journal of internal medicine.
[31] M Ferrari,et al. Nanomedicine and Society , 2009, Clinical pharmacology and therapeutics.
[32] Volker Wagner,et al. The emerging nanomedicine landscape , 2006, Nature Biotechnology.
[33] David M. Shaw,et al. Defining Nano, Nanotechnology and Nanomedicine: Why Should It Matter? , 2016, Sci. Eng. Ethics.
[34] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[35] Alex John London,et al. Predicting Harms and Benefits in Translational Trials: Ethics, Evidence, and Uncertainty , 2011, PLoS medicine.
[36] Gerald T. Ankley,et al. Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment: Adverse outcome pathways in ecological risk assessment , 2011 .
[37] Hugh J. Byrne,et al. Concern-driven integrated approaches to nanomaterial testing and assessment – report of the NanoSafety Cluster Working Group 10 , 2013, Nanotoxicology.
[38] Sebastian Hoffmann,et al. Integrated Testing Strategy (ITS) - Opportunities to better use existing data and guide future testing in toxicology. , 2010, ALTEX.
[39] Maria Dusinska,et al. Immunotoxicity, genotoxicity and epigenetic toxicity of nanomaterials: New strategies for toxicity testing? , 2017, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[40] Melvin E Andersen,et al. Dose-dependent transitions in mechanisms of toxicity. , 2004, Toxicology and applied pharmacology.
[41] Qasim Chaudhry,et al. Aligning nanotoxicology with the 3Rs: What is needed to realise the short, medium and long-term opportunities? , 2017, Regulatory toxicology and pharmacology : RTP.
[42] R. Duncan,et al. Nanomedicine(s) under the microscope. , 2011, Molecular pharmaceutics.
[43] Jo Anne Shatkin,et al. A multi-stakeholder perspective on the use of alternative test strategies for nanomaterial safety assessment. , 2013, ACS nano.
[44] Gurumurthy Ramachandran,et al. Handling Worker and Third-Party Exposures to Nanotherapeutics during Clinical Trials , 2012, Journal of Law, Medicine & Ethics.
[45] G. Oberdörster,et al. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology , 2010, Journal of internal medicine.
[46] Arthur G Erdman,et al. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. , 2013, Nanomedicine : nanotechnology, biology, and medicine.